Ticker League

Ovid Therapeutics (OVID) Profit Bridge

See what drove Ovid Therapeutics's net income from TTM through Q1 2025 to TTM through Q1 2026 — every line ranked by dollar impact, from revenue gains to taxes.

TTM

Revenue Change

+6.6M

Operating Income YoY

+16.28%

Net Income YoY

+3.20%

Net Margin Δ

+421782 bps

Net income bridge for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Net income: $806.00K+3.20%

Profit bridge breakdown for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Net Income−$24.97M
  • Revenue$6.57M
  • Cost of Revenue−$35.00K
  • Operating Expenses$2.74M
  • Other Income / Expense−$8.47M
  • Income Tax$0.00
  • Net Loss−$24.17M
Identity check: drivers reconcile to ΔNI within $0.00
Want the full P&L structure?Income Statement Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation